Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as ...

Field Medical announced today that it received FDA breakthrough device designation for its FieldForce pulsed field ablation ...

Four PFA systems have launched in the U.S. in the past year: Medtronic’s PulseSelect and Affera Sphere-9, Boston Scientific’s Farapulse and J&J's Varipulse. The Citi survey polled 36 ...

Citi raised the firm’s price target on Boston Scientific (BSX) to $107 from $98 and keeps a Buy rating on the shares. The firm also added the ...

Dr. Robert Ward prepares part of the FARAPULSE Pulsed Field Ablation System for a pulsed field ablation procedure to treat a patient with atrial fibrillation at Mayo Clinic Hospital, Saint Marys ...

AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...

BSX’s outperformance over the past year can be primarily attributed to its differentiated portfolio, strategic acquisitions like Farapulse, its category leadership strategy, and robust ...

Medtech executives expect the technology to help fuel their companies’ future growth. Boston Scientific CEO Mike Mahoney has ...

Valued at a market cap of $133.6 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets medical ...

1. Product Pipeline: The successful launch of new products, such as the U.S. Farapulse PFA, is expected to contribute to future growth. 2. Market Expansion: The potential indication expansion for ...

2 The FARAPULSE system (Boston Scientific), comprising a single-shot, pentaspline, multielectrode catheter (FARAWAVE) and a pulsed-field energy generator, was the first PFA system to become ...